We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Oruba Presents State-of-the-Art Self-Operating Uroflowmeters

By LabMedica International staff writers
Posted on 15 Nov 2023

Oruba Technology & Innovation (Langenfeld, Germany) is demonstrating its state-of-the-art self-operating uroflowmeters at MEDICA 2023. More...

Oruba is showcasing Oruflow, the world’s first self-operating uroflowmeter. As a point-of-care diagnostic device, it eases and accelerates the uroflowmetry process in a hygienic and comfortable atmosphere. The self-cleaning and hygienic point-of-care solution has revolutionized the process of uroflowmetry, making it a crucial part of every hospital and urology clinic. The self-operating uroflowmeter can be operated in easy steps. The patient first has to scan the hospital barcode to start the examination. The on-board screen helps the patients and guides them during the examination. Oruba Oruflow measures the test parameters and prepares the report. The patient then uses the hospital barcode to let Oruba Oruflow save the examination report into the hospital information system automatically. The patient can receive the results of the examination in seconds without any operator guidance.

As soon as the urination finishes, Oruba Oruflow prints the results out and cleans itself automatically. The patient can go to the doctor directly and the device gets ready for the next examination in one minute. Oruba Oruflow does not require an operator or nurse guidance and the patient does the test in an actual restroom comfort. Oruba Oruflow technology creates a hygienic and relaxed clinical atmosphere and prevents the unpleasant smell and dirt problem. Oruba Oruflow’s high-developed IoT technology and auto-notification system allows it to provide online technical service and solve the problem in minutes. The yearly maintenance and software upgrades are done from the Oruba HQ

Related Links:
Oruba Technology & Innovation 


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.